4//SEC Filing
Gasmi Mehdi 4
Accession 0001209191-20-043426
CIK 0001501756other
Filed
Jul 21, 8:00 PM ET
Accepted
Jul 22, 9:44 PM ET
Size
8.9 KB
Accession
0001209191-20-043426
Insider Transaction Report
Form 4
Gasmi Mehdi
VP, Pharmaceutical Development
Transactions
- Sale
Common Stock
2020-07-20$17.60/sh−5,000$87,978→ 274,442 total - Exercise/Conversion
Common Stock
2020-07-20$4.80/sh+5,000$24,000→ 279,442 total - Exercise/Conversion
Stock Option (Right to Buy)
2020-07-20−5,000→ 78,000 totalExercise: $4.80Exp: 2026-02-11→ Common Stock (5,000 underlying)
Footnotes (3)
- [F1]Shares sold pursuant to a 10b5-1 plan.
- [F2]Price reported is a weighted-average sales price. The shares were sold at prices ranging from $17.26 to $18.24. The reporting person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- [F3]Fully vested and exercisable.
Documents
Issuer
Adverum Biotechnologies, Inc.
CIK 0001501756
Entity typeother
Related Parties
1- filerCIK 0001614875
Filing Metadata
- Form type
- 4
- Filed
- Jul 21, 8:00 PM ET
- Accepted
- Jul 22, 9:44 PM ET
- Size
- 8.9 KB